What is it about?
Hyporesponsiveness to ESA may be directly evaluated as the dose of DA divided by Hb level at the 12th weeks of DA treatment. The cut-off value of the index was 5.2.
Featured Image
Photo by SHAMBHAVI SINGH on Unsplash
Why is it important?
ND-CKD patients with this index higher than 5.2 may have a higher risk for renal and CVD events in ND-CKD patients. A search for the causes of the poor response and measures for them should be recommended in such patients.
Perspectives
This index can be used to help make decisions such as changing from ESAs to HIF-PH inhibitors as treatment for renal anemia in ND-CKD.
Ichiei Narita
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences
Read the Original
This page is a summary of: Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study, PLoS ONE, November 2022, PLOS,
DOI: 10.1371/journal.pone.0277921.
You can read the full text:
Contributors
The following have contributed to this page
